Category Archives: HIV/AIDS. pre-exposure prophylaxis

  1. HIV/AIDS Organizations Tell FDA and Gilead Sciences: Don’t Delay HIV Prevention for Gay and Bisexual Men and Transgender Women

    [Press Release – October 18, 2011] Thirteen prominent U.S. HIV/AIDS organizations have issued an open letter to the U.S. Food and Drug Administration and Gilead Sciences calling for prompt regulatory review of pre-exposure prophylaxis (PrEP) for HIV prevention in gay and bisexual men and transgender women (men who have sex with men, or MSM). The letter urges Read More >>

    FDA, gay men, Gilead, HIV/AIDS. pre-exposure prophylaxis, IRMA, new prevention technologies, PrEP, transgendered
  2. Open Letter from HIV-Positive Prevention Advocates Rejects Misinformation about PrEP

    Close to 100 openly HIV-positive gay and bisexual men from across the United States and around the world have signed a new letter (http://tinyurl.com/pozPrEPletter) calling for an open discussion, “based on facts rather than on fear or misinformation,” of the challenges and opportunities presented by pre-exposure prophylaxis (PrEP) for HIV prevention in gay and bisexual men and Read More >>

    gay men, HIV/AIDS policy, HIV/AIDS. pre-exposure prophylaxis, IRMA, PrEP
  3. IRMA and AIDS Leaders Press Feds for Action on Promising New Prevention Tool

    Just months after an AIDS drug demonstrated reasonable efficacy in preventing HIV infection in controlled clinical trials, seven leading AIDS organizations are urging the U.S. government to act quickly to determine if the results could translate to the real world.   Today, at an HIV prevention meeting hosted by the U.S. Centers for Disease Control and Prevention (CDC), Read More >>

    HIV/AIDS policy, HIV/AIDS. pre-exposure prophylaxis, IRMA, pre-exposure prophylaxis, PrEP
  4. Two studies show that drugs used to treat AIDS can be used to prevent HIV infection, too

    [THIS IS HUGE!] via Washington Post, by David Brown Two new studies done in three African countries have shown for the first time that AIDS drugs taken daily can cut by more than half a person’s chance of becoming infected with HIV through heterosexual intercourse. The results, announced early Wednesday, provide more evidence that the drugs responsible Read More >>

    Africa, heterosexual epidemic, HIV/AIDS. pre-exposure prophylaxis, new prevention technologies, partners, Partners PrEP, PrEP
  5. Project Inform Reports: Financing Recommendations for PrEP

    Project Inform recently released a report titled Financing and Delivery Mechanisms to Increase Pre-Exposure Prophylaxis (PrEP) Access in Populations at High-Risk of HIV Infection. Available here, the report discusses issues related to financing for PrEP to ensure that it becomes a viable, accessible prevention method for MSM. Here as an excerpt from the executive summary of the Read More >>

    ARV, ARVs, Gilead, HIV/AIDS, HIV/AIDS policy, HIV/AIDS. pre-exposure prophylaxis, PrEP, Truvada
  6. If you’re HIV positive, safe sex isn’t just about condoms

    Via The Guardian, by Deborah Jack. As the HIV epidemic has evolved over three decades, the “just use a condom” message has remained the cornerstone of prevention. But stubbornly high levels of new HIV infections in the UK show we’ve struggled to always translate this simple message into real life. Most monogamous couples will decide to stop Read More >>

    condoms, HIV, HIV transmission, HIV/AIDS, HIV/AIDS. pre-exposure prophylaxis, new prevention technologies, PrEP, prevention, risk
  7. Factors Influencing the Emergence and Spread of HIV Drug Resistance Arising from Rollout of Antiretroviral Pre-Exposure Prophylaxis (PrEP)

    via PLoS One, by Abbas UL, Hood G, Wetzel AW, Mellors JW Abstract Background The potential for emergence and spread of HIV drug resistance from rollout of antiretroviral (ARV) pre-exposure prophylaxis (PrEP) is an important public health concern. We investigated determinants of HIV drug resistance prevalence after PrEP implementation through mathematical modeling. Methodology A model incorporating heterogeneity Read More >>

    HIV/AIDS policy, HIV/AIDS. pre-exposure prophylaxis, new prevention technologies, PrEP
  8. HIV PrEP Explained: Critical Prevention Opportunity

    via AIDS Treatment News, by John S. James This is a superb description of the iPrEx trial, with a smart analysis of it’s implications. A must-read. Excerpt: Why did so many of the study participants not take the Truvada? No one knows for sure at this time. But something unusual and unexpected happened in this study. This Read More >>

    gay men, HIV/AIDS policy, HIV/AIDS. pre-exposure prophylaxis, iPrEx, PrEP
  9. WSJ: Trial Halted on HIV Pill for Women

    [of interest: “There is research, as yet unpublished, showing that the concentration of tenofovir, when taken orally, is higher in rectal tissue than in vaginal tissue, said Timothy Mastro, an FHI vice president who spoke on behalf of the study. If so, the men might have had more of the drug than the women at the site Read More >>

    Africa, FEM-PrEP, HIV/AIDS. pre-exposure prophylaxis, women
  10. FHI to Initiate Orderly Closure of FEM-PrEP

    via FHI website Following a scheduled interim review of the FEM-PrEP study data, the Independent Data Monitoring Committee (IDMC) advised that the FEM-PrEP study will be highly unlikely to be able to demonstrate the effectiveness of Truvada [emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF)] in preventing HIV infection in the study population, even if it continued to Read More >>

    Africa, FEM-PrEP, HIV/AIDS. pre-exposure prophylaxis, women